Literature DB >> 3957566

Bacterial lipases and chronic blepharitis.

J M Dougherty, J P McCulley.   

Abstract

Eyelids and conjunctivae of 36 normal individuals and 60 patients from six clinical groups of chronic blepharitis were cultured for aerobic and anaerobic bacteria. The most common species isolated were coagulase-negative staphylococci (C-NS) and Propionibacterium acnes. All strains of these species, and all Staphylococcus aureus strains isolated were tested for the ability to break down triglycerides, cholesterol esters, and fatty waxes. Each strain was incubated independently with appropriate substrates in nutrient media. Each medium was then extracted and assayed for the presence of substrate hydrolysis products by thin-layer chromatography. The percentage of strains capable of hydrolyzing a particular substrate was determined for each individual. S. aureus was a consistent and strong lipase producer, able to hydrolyze all three substrates. P. acnes was able to hydrolyze triolein and behenyl oleate but not cholesteryl oleate. No differences were observed among groups for P. acnes or S. aureus. C-NS showed a high degree of strain variability. Eighty-three percent of C-NS strains could hydrolyze triolein, 82% behenyl oleate, and 40% cholesteryl oleate. Significant group differences were seen in the percentage of lipase positive C-NS strains isolated per individual. Patients in the mixed staphylococcal/seborrheic, meibomian seborrheic, secondary meibomitis, and the meibomian keratoconjunctivitis (MKC) groups harbored significantly more C-NS strains capable of hydrolyzing cholesteryl oleate than did normal individuals. Patients in the meibomian seborrheic, secondary meibomitis, and MKC groups harbored significantly more C-NS strains capable of hydrolyzing behenyl oleate than did normals. No group differences were seen among groups with triolein hydrolyzing C-NS strains.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3957566

Source DB:  PubMed          Journal:  Invest Ophthalmol Vis Sci        ISSN: 0146-0404            Impact factor:   4.799


  41 in total

1.  Blepharitis: remains a diagnostic enigma. A role for tea tree oil shampoo?

Authors:  P Hossain; A Konstantopoulos
Journal:  Eye (Lond)       Date:  2015-08-21       Impact factor: 3.775

Review 2.  Interventions for chronic blepharitis.

Authors:  Kristina Lindsley; Sueko Matsumura; Elham Hatef; Esen K Akpek
Journal:  Cochrane Database Syst Rev       Date:  2012-05-16

3.  Tear film breakup and structure studied by simultaneous video recording of fluorescence and tear film lipid layer images.

Authors:  P Ewen King-Smith; Kathleen S Reuter; Richard J Braun; Jason J Nichols; Kelly K Nichols
Journal:  Invest Ophthalmol Vis Sci       Date:  2013-07-22       Impact factor: 4.799

Review 4.  Four characteristics and a model of an effective tear film lipid layer (TFLL).

Authors:  P Ewen King-Smith; Melissa D Bailey; Richard J Braun
Journal:  Ocul Surf       Date:  2013-07-12       Impact factor: 5.033

5.  [Meibomian glands : part IV. Functional interactions in the pathogenesis of meibomian gland dysfunction (MGD)].

Authors:  E Knop; N Knop
Journal:  Ophthalmologe       Date:  2009-11       Impact factor: 1.059

6.  Ophthaproblem. Chalazion.

Authors:  S Sharma
Journal:  Can Fam Physician       Date:  1998-06       Impact factor: 3.275

Review 7.  [Chronic blepharitis. Pathogenesis, clinical features, and therapy].

Authors:  C Auw-Haedrich; T Reinhard
Journal:  Ophthalmologe       Date:  2007-09       Impact factor: 1.059

Review 8.  [Blepharitis].

Authors:  T Kaercher; H Brewitt
Journal:  Ophthalmologe       Date:  2004-11       Impact factor: 1.059

Review 9.  Understanding and analyzing meibomian lipids--a review.

Authors:  Igor A Butovich; Thomas J Millar; Bryan M Ham
Journal:  Curr Eye Res       Date:  2008-05       Impact factor: 2.424

10.  Efficacy and safety of mercuric oxide in the treatment of bacterial blepharitis.

Authors:  R A Hyndiuk; E M Burd; A Hartz
Journal:  Antimicrob Agents Chemother       Date:  1990-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.